Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
PETALUMA, Calif., Oct. 27, 2016 -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), today announced that the financial results for its fiscal second quarter 2017, ended September 30, 2016, will be released after the U.S. markets close on November 10, 2016. The earnings release will be followed by a conference call at 1:30 p.m. PST on November 10, 2016, to discuss fiscal second quarter results.
Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the internet may do so at http://ir.oculusis.com/events.cfm.
A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 94494840. A webcast replay will be available on the site at http://ir.oculusis.com/events.cfm for one year following the call.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.
Media and Investor Contact: Oculus Innovative Sciences, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 [email protected]
